Home › Companies › Protalix Biotherapeutics, Inc.

Protalix Biotherapeutics, Inc. (PLX) proxy voting records

How asset managers voted at Protalix Biotherapeutics, Inc.’s shareholder meetings, one page per proxy season, compiled from the votes funds and managers report on SEC Form N-PX and the company’s own results on Form 8-K.

• TickerPLX
• CUSIP issuer number74365A
• SEC CIK1006281

Recent shareholder votes

• June 25, 2026 annual meeting (2025-2026 proxy season): 11 items in Protalix Biotherapeutics, Inc.'s official results (Form 8-K, filed June 25, 2026); lowest support 80% of votes cast (Approval of the Plan to increase the number of shares of common…). Full results and how funds voted.
• June 27, 2024 annual meeting (2023-2024 proxy season): 10 items in Protalix Biotherapeutics, Inc.'s official results (Form 8-K, filed June 28, 2024); lowest support 54.6% of votes cast (Elect Director: Amos Bar Shalev). Full results and how funds voted.

Each line is the company’s own Form 8-K tally as shown on that season’s page; support is FOR as a share of votes cast.

Proxy seasons

Earlier seasons list this company under the name PROTALIX BIOTHERAPEUTICS INC., as its holders filed it.

Explore Protalix Biotherapeutics, Inc. in the interactive database

The seasons are grouped by the issuer number in the company’s CUSIP, not by its name. Ticker as listed by the SEC on November 6, 2026. This page is rebuilt weekly; built November 9, 2026.